Syndecan-1 (CD138) expression in different cancers is of upcoming clinical interest as precise drugs targeting CD138 are now being evaluated in clinical trials, particularly in plasma cell neoplasms. This evidence concerns the gene SDC1 and plasma cell neoplasm.